Abstract
The cysteine hydrolase N ω,N ω-dimethyl-L-arginine dimethylaminohydrolase-1 (DDAH-1) is an important regulator of NO production through the degradation of endogenous Nω-methylated arginines, that are competitive inhibitors for nitric oxide synthase (NOS). Consequently, DDAH-1 is a target for pharmacological drug design to regulate NO production. The appearance of a second isoform DDAH-2, which was assigned through sequence comparison, requires detailed knowledge about the properties of both proteins. This study represents the first attempt for a structural and functional characterization of DDAH-2. However, lack in enzymatic activity together with structural consideration based on a homology model places the designation as a DDAH enzyme into question. On the other hand, it is shown that DDAH-2 is a substrate for two protein-arginine methyltransferases, CARM-1 and PRMT-6, which supports the participation of DDAH-2 in the metabolism of side-chain methylated arginines.
Keywords: Arginine methylation, CARM-1, DDAH, Dimethylarginine dimethylaminohydrolase, g6a, PRMT-6
Letters in Drug Design & Discovery
Title: Toward the Development of Inhibitors Directed against Mammalian DDAH Proteins: Considerations from Homology Modeling of DDAH-2 and DDAH Activity Tracing in Tissue Homogenate
Volume: 4 Issue: 8
Author(s): Markus Knipp
Affiliation:
Keywords: Arginine methylation, CARM-1, DDAH, Dimethylarginine dimethylaminohydrolase, g6a, PRMT-6
Abstract: The cysteine hydrolase N ω,N ω-dimethyl-L-arginine dimethylaminohydrolase-1 (DDAH-1) is an important regulator of NO production through the degradation of endogenous Nω-methylated arginines, that are competitive inhibitors for nitric oxide synthase (NOS). Consequently, DDAH-1 is a target for pharmacological drug design to regulate NO production. The appearance of a second isoform DDAH-2, which was assigned through sequence comparison, requires detailed knowledge about the properties of both proteins. This study represents the first attempt for a structural and functional characterization of DDAH-2. However, lack in enzymatic activity together with structural consideration based on a homology model places the designation as a DDAH enzyme into question. On the other hand, it is shown that DDAH-2 is a substrate for two protein-arginine methyltransferases, CARM-1 and PRMT-6, which supports the participation of DDAH-2 in the metabolism of side-chain methylated arginines.
Export Options
About this article
Cite this article as:
Knipp Markus, Toward the Development of Inhibitors Directed against Mammalian DDAH Proteins: Considerations from Homology Modeling of DDAH-2 and DDAH Activity Tracing in Tissue Homogenate, Letters in Drug Design & Discovery 2007; 4 (8) . https://dx.doi.org/10.2174/157018007782794572
DOI https://dx.doi.org/10.2174/157018007782794572 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Lessons we Learned from High-Throughput and Top-Down Systems Biology Analyses about Glioma Stem Cells
Current Pharmaceutical Design Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Inhibitors of Cholinesterases in Pharmacology: the Current Trends
Mini-Reviews in Medicinal Chemistry Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Cytotoxic Effects of Chemotherapeutic Drugs and Heterocyclic Compounds at Application on the Cells of Primary Culture of Neuroepithelium Tumors
Medicinal Chemistry Green Chemistry Starting from 2H-Pyran-2-one Derivatives
Current Green Chemistry Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor
Current Pharmaceutical Design Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Small Molecule Regulators Targeting NAD<sup>+ </sup>Biosynthetic Enzymes
Current Medicinal Chemistry Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry